Circulation,
Год журнала:
2024,
Номер
150(4), С. 272 - 282
Опубликована: Июнь 6, 2024
BACKGROUND:
A
hypothetical
concern
has
been
raised
that
sacubitril/valsartan
might
cause
cognitive
impairment
because
neprilysin
is
one
of
several
enzymes
degrading
amyloid-β
peptides
in
the
brain,
some
which
are
neurotoxic
and
linked
to
Alzheimer-type
dementia.
To
address
this,
we
examined
effect
compared
with
valsartan
on
function
patients
heart
failure
preserved
ejection
fraction
a
prespecified
substudy
PARAGON-HF
(Prospective
Comparison
Angiotensin
Receptor
Neprilysin
Inhibitor
With
Blocker
Global
Outcomes
Heart
Failure
Preserved
Ejection
Fraction).
METHODS:
In
PARAGON-HF,
serial
assessment
was
conducted
subset
Mini-Mental
State
Examination
(MMSE;
score
range,
0–30,
lower
scores
reflecting
worse
function).
The
primary
analysis
this
change
from
baseline
MMSE
at
96
weeks.
Other
post
hoc
analyses
included
decline
(fall
≥3
points),
(MMSE
<24),
or
occurrence
dementia-related
adverse
events.
RESULTS:
Among
2895
measured,
1453
were
assigned
1442
valsartan.
Their
mean
age
73
years,
median
follow-up
32
months.
mean±SD
randomization
27.4±3.0
group,
10%
having
an
<24;
corresponding
numbers
nearly
identical
group.
weeks
group
−0.05
(SE,
0.07);
−0.04
(0.07).
between-treatment
difference
week
−0.01
(95%
CI,
−0.20
0.19;
P
=0.95).
Analyses
≥3-point
MMSE,
decrease
<24,
events,
combinations
these
showed
no
between
No
found
subgroup
tested
for
apolipoprotein
E
ε4
allele
genotype.
CONCLUSIONS:
Patients
had
relatively
low
scores.
Cognitive
change,
measured
by
did
not
differ
treatment
fraction.
REGISTRATION:
URL:
https://www.clinicaltrials.gov
;
Unique
identifier:
NCT01920711.
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(4), С. 3321 - 3321
Опубликована: Фев. 7, 2023
Neurodegenerative
disorders
are
characterised
by
progressive
neuron
loss
in
specific
brain
areas.
The
most
common
Alzheimer’s
disease
and
Parkinson’s
disease;
both
cases,
diagnosis
is
based
on
clinical
tests
with
limited
capability
to
discriminate
between
similar
neurodegenerative
detect
the
early
stages
of
disease.
It
that
time
a
patient
diagnosed
disease,
level
neurodegeneration
already
severe.
Thus,
it
critical
find
new
diagnostic
methods
allow
earlier
more
accurate
detection.
This
study
reviews
available
for
diseases
potentially
interesting
technologies.
Neuroimaging
techniques
widely
used
practice,
such
as
magnetic
resonance
imaging
(MRI)
positron
emission
tomography
(PET)
have
significantly
improved
quality.
Identifying
biomarkers
peripheral
samples
blood
or
cerebrospinal
fluid
major
focus
current
research
diseases.
discovery
good
markers
could
preventive
screening
identify
asymptomatic
process.
These
methods,
combination
artificial
intelligence,
contribute
generation
predictive
models
will
help
clinicians
diagnosis,
stratification,
prognostic
assessment
patients,
leading
improvements
treatment
quality
life.
The Egyptian Journal of Neurology Psychiatry and Neurosurgery,
Год журнала:
2023,
Номер
59(1)
Опубликована: Ноя. 7, 2023
Abstract
Alzheimer’s
disease
(AD)
is
a
form
of
dementia
marked
by
the
accumulation
neuritic
plaques
and
neurofibrillary
tangles
through
action
GSK-3β
with
both
significant
epidemiological
clinical
impact.
Current
pharmacological
treatment
approaches
are
focused
on
symptomatic
relief
aims
to
suppress
AD’s
progression
rather
than
modification.
This
issue
has
triggered
further
investigations
about
tau
pathology
as
an
important
component
in
pathophysiology,
one
them
being
Akt
signaling
pathway.
Based
problem
served
AD,
combined
non-existence
conclusive
therapy
for
this
disease;
hence,
study
strives
investigate
potential
therapeutical
benefit
towards
AD.
A
total
82
studies
included,
consisting
national
international
articles
creating
narrative
review
based
PRISMA
checklist.
Variables
searched
study,
include
(AD),
signaling,
serine-9
phosphorylation,
GSK-3β.
Tau
protein
been
mainstay
physiopathology
which
largely
influenced
expression.
shown
inactivate
phosphorylation.
Thus,
modulating
optimizing
pathway
present
encouraging
prospects
development
innovative
efficacious
therapeutic
strategies
addressing
Several
have
tried
estimate
harm
well
dose–effect
relationship
between
concluding
promising
beneficial
effect
AD
therapy.
Here,
we
show
effects
theoretical
empirical
standpoints.
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(22), С. 11955 - 11955
Опубликована: Ноя. 7, 2024
Alzheimer's
disease
(AD)
and
type
2
diabetes
mellitus
(T2DM)
are
two
prevalent
conditions
that
present
considerable
public
health
issue
in
aging
populations
worldwide.
Recent
research
has
proposed
a
novel
conceptualization
of
AD
as
"type
3
diabetes",
highlighting
the
critical
roles
insulin
resistance
impaired
glucose
metabolism
pathogenesis
disease.
This
article
examines
implications
this
association,
exploring
potential
new
avenues
for
treatment
preventive
strategies
AD.
Key
evidence
linking
to
emphasizes
metabolic
processes
contribute
neurodegeneration,
including
inflammation,
oxidative
stress,
alterations
signaling
pathways.
By
framing
within
context,
we
can
enhance
our
understanding
its
etiology,
which
turn
may
influence
early
diagnosis,
plans,
measures.
Understanding
manifestation
opens
up
possibility
employing
therapeutic
incorporate
lifestyle
modifications
use
antidiabetic
medications
mitigate
cognitive
decline.
integrated
approach
improve
patient
outcomes
deepen
comprehension
intricate
relationship
between
neurodegenerative
diseases
disorders.
Food & Function,
Год журнала:
2024,
Номер
15(17), С. 8712 - 8728
Опубликована: Янв. 1, 2024
Quercetin
exerted
antioxidant
and
anti-inflammatory
properties
to
protect
brain
neuronal
health.
It
also
ameliorated
Aβ
deposition,
regulated
APP,
BACE-1
tau
hyperphosphorylation
in
brain,
improved
neurobehavioral
cognitive
parameters.
